To include your compound in the COVID-19 Resource Center, submit it here.

Ganetespib: Phase II data

Additional data from patients in the K-Ras wild-type cohort of an open-label, U.S. Phase II trial showed that ganetespib produced 1 durable partial response and 7 cases

Read the full 270 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE